Toronto, Ontario–(Newsfile Corp. – July 1, 2025) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) announces that its Board of Directors granted 2,465,000 stock options to directors, officers, employees and consultants (the “Optionees”) pursuant to the terms and subject to the conditions of the Company’s Incentive Stock Option Plan.
The 2,465,000 stock options were granted to directors, officers, employees and consultants on June 30, 2025, and have an exercise price of C$0.23. These options are exercisable for five years from the date of grant and the options shall vest in thirds on the date of grant and each of the first and second anniversaries of the dates of grant, always subject to the Optionee’s maintenance of continuous status as an employee, director, officer, consultant or service provider of the Company.
In addition to the options noted above, and as previously announced on March 31, 2025, the Directors of the Company agreed to receive their quarterly director fees for 2025 in the form of stock options in lieu of cash. On June 30th, 2025, each director was granted 27,000 stock options at an exercise price of $0.23. An aggregate of 108,000 stock options were granted to directors in lieu of their director fees for the second financial quarter of 2025. All such stock options will be exercisable for a period of three years from the date of grant and vested immediately upon grant. In the event a director intends to exercise such stock options, such director shall be solely responsible for paying the entirety of the exercise price.
About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CULVER CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced the launch of two new indie titles, Robots at Midnight and Zombie Rollerz: The Last Ship, in the month of June. These releases mark a strategic expansion into distinct game and player demographics, showcasing Snail’s ongoing commitment to fostering creativity and innovation across its global portfolio.
Robots at Midnight, developed by Toronto based studio Finish Line Games, represents Snail Games’ strategic entry into a younger segment of the gaming market. Designed as an accessible, entry-level Souls-like game, it introduces the genre’s core mechanics in a more user-friendly format, lowering the barrier to entry for wider appeal. The game specifically targets the younger Gen Z and Gen Alpha players who are just beginning to engage with more complex gameplay experiences. Backed in part by Canada Media Fund, the game is led by studio co-founder Daniel Posner, whose background in education and interactive media bridges entertainment and learning. To celebrate the launch of Robots at Midnight and the 2.1M+ viewer minutes watched on Twitch, the team is hosting a community event where players can win DIY robot kits encouraging real world creativity inspired by in-game exploration. For Snail Games, its investment in games like Robots at Midnight is a long-term strategy to captivate the next generation of gamers and creators. With Gen Alpha projected to become the most digitally fluent and commercially influential generation to date, early engagement aims to build brand loyalty and position the Company to meet the future demands of an evolving global market.
Zombie Rollerz: The Last Ship, developed by Zing Games, comes from a seasoned studio with a track record of success; its previous titles, including the predecessor Zombie Rollerz: Pinball Heroes, have collectively surpassed 10 million downloads. The latest installment in the Zombie Rollerz franchise blends fast-paced roguelite mechanics with tower defense survival strategy to deliver a highly replayable, content-rich experience. With a positive Steam rating at launch and a distinctive visual style that appeals to casual and core gamers alike, Zombie Rollerz: The Last Ship demonstrates the strength of Zing Games’ IP and Snail’s ability to identify and scale high-performing indie titles.
Together, Robots at Midnight and Zombie Rollerz: The Last Ship exemplifies Snail Games’ strategic focus on widening its portfolio and deepening market penetration across multiple player segments. By introducing accessible gameplay in an underserved genre to engage Gen Alpha players and scaling emerging IPs, Snail is actively expanding its presence across diverse markets. These launches reflect a deliberate approach to portfolio diversification – one that balances genre innovation, long-term revenue opportunities, and global audience growth as Snail continues to evolve and embrace the next-generation of interactive entertainment.
For creators interested in covering Zombie Rollerz: The Last Ship or Robots at Midnight please reach out to creatordirect@noiz.gg.
About Snail, Inc. Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.
Forward-Looking Statements This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding (i) Snail showcasing its ongoing commitment to fostering creativity and innovation across its global portfolio, (ii) Snail’s long-term investment in the next generation of gamers and creators, (iii) Gen Alpha projected to become the most digitally fluent and commercially influential generation to date and (iv) Gen Alpha projected to become the most digitally fluent and commercially influential generation to date. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company’s Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Investor Contact: John Yi and Steven Shinmachi Gateway Group, Inc. 949-574-3860 SNAL@gateway-grp.com
Atlanta, GA, July 1, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 9.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.65 per unit in a public offering. The Company will issue warrants to purchase up to approximately 18.5 million shares of common stock. The warrants will have an exercise price of $0.65 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance.
Roth Capital Partners is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.
The shares in the offering described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-288085) previously filed with the Securities and Exchange Commission (the ‘SEC’) and declared effective by the SEC on June 30, 2025. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, relating to the offering that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Roth Capital Partners, LLC at 888 San Clemente Drive, Newport Beach, CA 92660, by phone at (800) 678-9147 or by accessing the SEC’s website, www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey. The poster presentations highlight MAIA’s lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey.
Poster Presentation 1
Abstract title: “Telomere-targeting therapeutics RiboTHIO and THIO synergize with radiotherapy and immune checkpoint blockade to suppress lung tumor growth”
Abstract title: “The effects of telomerase mediated telomere-targeting novel drug candidate compounds on oxidative DNA damage and DNA repair on A549 cells”
“We appreciate the opportunity to participate at the FEBS Congress where the outstanding merits of our first-in-class cancer telomere targeting agents will be featured before a gathering of the top European academic researchers and scientists.” said MAIA Chairman and CEO Vlad Vitoc, M.D. “These scientific findings further illustrate the potential of our current and next-generation treatments to synergize with therapies used in several cancer indications.”
The most recent data from MAIA’s THIO-101 pivotal Phase 2 clinical trial of ateganosine as a treatment for non-small cell lung cancer (NSCLC) showed median overall survival (OS) of 17.8 months1 in a heavily pre-treated population.
____________________
1 May 15, 2025, data cut
About Federation of European Biochemical Societies (FEBS)
Founded on 1st January 1964, FEBS has become one of Europe’s largest organizations in the molecular life sciences. It has over 30,000 members across 39 biochemistry and molecular biology Societies (its ‘Constituent Societies’) in different countries of Europe and regions. As a grass-roots organization, FEBS thereby provides a voice to a large part of the academic research and teaching community in Europe and beyond.
About Turkish Biochemical Society (TBS)
Established in 1975 in Ankara, the TBS is the Turkish home of basic and clinical biochemistry. We unite researchers across diverse fields such as biochemistry, molecular biology, biotechnology, molecular medicine, and bioinformatics under one visionary umbrella. Our mission is to foster a vibrant community where ideas flourish, knowledge expands, and the frontiers of science and medicine are continuously pushed forward.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
NORWOOD, Mass., July 01, 2025 (GLOBE NEWSWIRE) — Following today’s announcement that Delaware will commence adult-use sales of cannabis, MariMed CEO Jon Levine released the following statement:
“We are excited to participate in the expansion of Delaware’s cannabis program to include adult-use sales. Our Delaware business unit, First State Compassion (“FSC”), was the first licensed operator in the state 10 years ago, and since then we have proudly served the state’s medical cannabis patients. The investments we’ve made in our facilities, brands, and employees have positioned us to be the leader in what promises to be a strong, high-growth cannabis market.
“We are looking forward to opening our doors to many more residents and the nearly 30 million tourists who visit the state annually. In anticipation of this expansion, we have already made improvements at both of our two FSC dispensaries in Wilmington and Lewes. They ensure we can easily manage the increased customer traffic and continue to deliver the exceptional experience and product selection that our customers love about visiting an FSC location.
“In order to meet this rise in demand, we have also begun scaling production at our cultivation and processing facilities in Wilmington and Milford. That includes Betty’s Eddies chews, the number one edible in the state, and our FSC and Nature’s Heritage flower brands, which are both top five sellers.
“We thank State Representative Osienski, State Senator Paradee, State Senator Hoffner, and Marijuana Commissioner Sanderlin for their leadership in growing Delaware’s cannabis industry in a safe and responsible manner for both consumers and operators.”
About MariMed MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.
The annual Russell Index reconstitution, which took effect after market close on Friday, June 27, 2025, marked a significant milestone in the small and mid-cap investment landscape. This 37th annual reconstitution represents the final annual rebalancing before FTSE Russell transitions to a semi-annual schedule, making it particularly noteworthy for investors focused on emerging growth companies.
Historically, Russell Reconstitution Day represents the biggest trading close of the year, with last year’s event generating $220 billion in U.S. equity trading volume. This year’s rebalancing has brought several compelling additions to the Russell indexes, particularly in the biotechnology and technology sectors, offering new opportunities for investors seeking exposure to innovative small and mid-cap companies.
Notable New Additions to Watch
Among the most intriguing additions to the Russell indexes this year are several companies that exemplify the dynamic nature of today’s small-cap market. Tonix Pharmaceuticals (TNXP) announced its inclusion in both the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, representing a significant validation of the fully-integrated biotechnology company’s market position and growth trajectory.
Tonix’s addition is particularly noteworthy given the company’s focus on developing treatments across multiple therapeutic areas. The inclusion in these widely-followed indexes is expected to increase institutional investor attention and potentially improve liquidity for the stock, making it more accessible to a broader range of portfolio managers and ETF providers.
Eledon Pharmaceuticals (ELDN) represents another compelling story in the clinical-stage biopharmaceutical space. The company focuses on developing immune-modulating therapies for life-threatening conditions, positioning it at the forefront of innovative medical treatment development. With analyst price targets averaging $10.40 and ranging from $8.00 to $16.00, representing a potential 230% upside from recent trading levels, the stock demonstrates the significant growth potential that Russell Index inclusion can help unlock.
Comstock (LODE) and SKYX Platforms (SKYX) round out a diverse group of new additions that span multiple sectors, from natural resources to technology platforms. These companies represent the type of emerging businesses that the Russell reconstitution process is designed to capture, ensuring that the indexes remain representative of the evolving U.S. equity market landscape.
The Russell reconstitution process serves as a crucial barometer for middle market health and provides institutional validation for growing companies. The process realigns membership across the Russell 1000, Russell 2000, Russell 3000, and Russell Microcap indexes to reflect changes in market capitalization and structure, ensuring these benchmarks accurately represent the current market environment.
For investors focused on small and mid-cap opportunities, these new additions represent companies that have demonstrated sufficient growth, liquidity, and market acceptance to meet Russell’s stringent inclusion criteria. The reconstitution process, which began on April 30 and culminated with the June 27 implementation, involves comprehensive evaluation of company fundamentals and market positioning.
As the Russell indexes transition to semi-annual reconstitution in the future, this year’s additions take on added significance, representing the final cohort selected through the traditional annual process that has guided small-cap investing for decades.
To learn more about emerging opportunities in the small and mid-cap market, join us at Noble Capital Markets’ upcoming Virtual Equity Conference on October 8-9, where we’ll feature presentations from promising growth companies and insights from leading market experts.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Approval Delay Is Not A Surprise. Unicycive announced that it has received a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). This was expected following the announcement earlier this month stating that the FDA manufacturing inspection had found deficiencies with one of the OLC contract manufacturers. The company has switched to one of its other manufacturers, which we believe can resolve the issues quickly. We see approval possible around 4Q25 to 1Q26.
Plans To Address The Issues. Unicycive plans to hold a Type A meeting with the FDA to determine its requirements for resolution of the issues cited in the CRL. The company’s second manufacturer already produces OLC and has been generating data for FDA certification. This should allow Unicycive to submit any additional data requested quickly to resolve the issue.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Capital Raise. Kratos completed its previously announced offering of Kratos common stock, raising $575 million in gross proceeds, at a public offering price of $38.50 per share, for a total of 14,935,065 shares of common stock, which includes the exercise of the underwriter’s option to purchase additional shares. Net proceeds from the offering were approximately $556 million. Noble Capital participated as a co-manager of the offering.
Use of Proceeds. Kratos expects to use the net proceeds of the offering to (i) fund investments and capital expenditures to scale and successfully execute on large, mission critical National Security priorities related to existing programs, recent program awards and significant high-probability pipeline opportunities; (ii) to finance important customer and program targeted acquisitions; (iii) and for general corporate purposes.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Awards. Yesterday, Great Lakes provided an update on some recent awards. Each of the awards adds to the Company’s significant backlog, which stood at approximately $1 billion with an additional $265 million in low bids and options pending award at the end of the first quarter. The large backlog, with a majority being higher margin capital projects, provides strong visibility for 2025 and into 2026.
Woodside LNG. The Company received Notice to Proceed from Bechtel Energy for dredging work on the Woodside Louisiana LNG project. The first phase of work, which was awarded in the second quarter of 2025, includes the construction of a ship berthing basin for use by large LNG carriers, with potential for award of two options to expand the scope of construction for additional ship berths. Dredging operations are expected to commence in early 2026.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
The American labor market delivered a surprise in May, with job openings climbing to their highest point in over six months, according to fresh government data that has caught economists and Federal Reserve watchers off guard.
The Bureau of Labor Statistics reported Tuesday that available positions reached 7.76 million at the end of May, representing a substantial jump from April’s 7.39 million openings. This figure significantly exceeded analyst predictions, which had anticipated job openings would remain relatively flat at approximately 7.3 million positions.
The unexpected surge in available positions marks the strongest showing for job openings since November 2024, suggesting that despite broader economic uncertainties, employers continue to maintain robust demand for workers across various sectors.
While the job opening data painted an optimistic picture, other components of the Job Openings and Labor Turnover Survey revealed a more nuanced employment landscape. Hiring activity actually declined during the month, with companies bringing on 5.5 million new employees compared to 5.61 million in April. This translated to a hiring rate of 3.4%, down from the previous month’s 3.5%.
The data reveals what labor economists have characterized as a market in equilibrium, where demand for workers remains strong but actual hiring activity has moderated from the rapid pace seen in recent years. Both hiring and voluntary quit rates are currently operating near decade-low levels, indicating a more measured approach to job market transitions.
Interestingly, the quit rate—often viewed as a barometer of worker confidence—edged upward to 2.1% from April’s 2.0%. This modest increase suggests that while employees remain cautious about making career moves, some are beginning to show renewed confidence in finding alternative employment opportunities.
The labor market data arrives at a critical juncture for monetary policy discussions. Financial markets are closely monitoring employment trends as the Federal Reserve weighs potential interest rate adjustments in response to evolving economic conditions.
Current market expectations indicate approximately a 23% probability of a rate cut at the Fed’s July meeting, with odds rising to 96% for at least one reduction by the September meeting. The stronger-than-expected job opening figures could influence these calculations, as robust labor demand typically supports arguments against immediate monetary easing.
The employment picture becomes more complex when considering recent policy developments, including the implementation of new trade measures under the Trump administration. Economists are watching for any signs that tariff policies might be affecting hiring patterns or business confidence across different industries.
Market participants will receive additional labor market insights Thursday when the Bureau of Labor Statistics releases the comprehensive June employment report. Economists are forecasting a continued moderation in hiring activity, with projections calling for 110,000 new nonfarm payroll additions—a notable decline from recent months.
The unemployment rate is expected to tick slightly higher to 4.3%, which would represent a modest increase from the current 4.2% level. If these projections prove accurate, they would reinforce the narrative of a labor market that remains fundamentally healthy but is operating at a more sustainable pace than the breakneck hiring seen in the post-pandemic recovery period.
As one economist noted, while hiring activity remains below historical norms, the combination of low layoff rates and steady job creation suggests the labor market has achieved a state of relative stability rather than deterioration. This balance could prove beneficial for both workers and employers as the economy navigates ongoing policy transitions and global economic uncertainties.
CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) — GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace, today announced it has entered into an amendment with its lenders under the Company’s existing credit agreement in order to, among other things, provide covenant adjustments as well as extend the maturity of the Company’s revolving credit facility through September 30, 2025. The amendment also provides consent for the Company to pursue a receivables financing (such consent also covering a securitization transaction) as the parties continue to work toward a comprehensive financing plan intended to alleviate the Company’s recent going concern position, strengthen the Company’s financial foundation, provide flexibility and position GoHealth for future sustainable and cash generating growth.
“This amendment highlights broad-based support from stakeholders across the capital structure and allows the Company to focus on longer-term strategic priorities,” said Vijay Kotte, Chief Executive Officer of GoHealth. “For nearly a decade, GoHealth has been a leader in supporting Medicare consumers as they assess their benefit options and enroll in Medicare Advantage plans. These actions, announced today, and the expected subsequent transactions are intended to reinforce this leadership while positioning us well for the future.”
Additional terms of the amendment are set forth in GoHealth’s Current Report on Form 8-K to be filed with the Securities and Exchange Commission on June 30, 2025.
About GoHealth
GoHealth is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth’s proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its unbiased, technology-driven marketplace coupled with highly skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since GoHealth’s inception. For more information, visit https://www.gohealth.com/.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding GoHealth’s future liquidity, going concern and related plans, the negotiation of a comprehensive financing plan, subsequent transactions and the pursuit of a receivables financing, results of operations and financial position, business strategy and plans and objectives of management for future operations are forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “aims,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “likely,” “future” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions, projections and other statements about future events that are based on current expectations and assumptions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although GoHealth believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.
These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the Company’s inability to alleviate the going concern, failure to obtain the benefits from the announced amendment, failure to pursue and secure a comprehensive financing plan, subsequent transaction or a receivables facility, failure to improve operational performance, the factors described in the sections titled “Summary Risk Factors,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in GoHealth’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (“2024 Annual Report on Form 10-K”), Quarterly Report on Form 10-Q for the first quarter ended March 31, 2025 (“Q1 2025 Quarterly Report on Form 10-Q”) and in its other filings with the Securities and Exchange Commission. The factors described in GoHealth’s 2024 Annual Report on Form 10-K and the Q1 2025 Quarterly Report on Form 10-Q should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in our other filings with the Securities and Exchange Commission.
You should read this press release and the documents that GoHealth references in this press release completely and with the understanding that its actual future results may be materially different from what it expects. GoHealth qualifies all of its forward-looking statements by these cautionary statements. Except as required by applicable law, GoHealth does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Refinancing extends maturity to 2030 and increases flexibility
NEW ALBANY, OHIO, June 30, 2025 (GLOBE NEWSWIRE) — Commercial Vehicle Group (together with its subsidiaries, the “Company” or “CVG”) (NASDAQ: CVGI), a diversified industrial products and services company, today announced that on June 27, 2025 it had closed on $210 million in senior secured credit facilities, consisting of (i) a $95 million senior secured term loan facility (the “Term Loan”) with TCW Asset Management Company LLC (together with certain of its affiliates, the “TCW Group”), as agent, and (ii) a $115 million senior secured asset-based revolving credit facility (the “ABL Facility” and together with the Term Loan, the “Senior Secured Credit Facilities”) with Bank of America, N.A., as agent. The ABL Facility amended and restated the Company’s existing senior secured revolving credit facility with Bank of America, N.A., as agent (the “Existing Facility”), and a portion of the proceeds of the Senior Secured Credit Facilities was used to refinance outstanding obligations under the Existing Facility in an aggregate principal amount of $120,100,000.
Andy Cheung, Chief Financial Officer, said, “We are pleased to announce the successful refinancing of our debt facilities maturing in 2027, which marks an important milestone as we continue to advance our strategic operational initiatives. The new facilities provide a long runway of funding certainty and increased financial flexibility as we look to drive further cost reductions, margin improvement, and overall operational efficiency. Moving forward, we remain committed to deleveraging the balance sheet through free cash generation and disciplined debt paydown.”
Term Loan of $95 million
Obligations under the Term Loan will mature on June 27, 2030.
The Term Loan will have tiered interest costs based on the consolidated total leverage ratio ranging from SOFR plus 8.75% with a leverage ratio < 3.50x to SOFR plus 10.75% with a leverage ratio > 6.25x. The SOFR floor is 2.00%. The initial interest rate payable under the Term Loan is SOFR plus 9.75%.
Until June 28, 2028, voluntary prepayments of the Term Loan are subject to a premium, calculated as a percentage of the obligations so prepaid under the Term Loan, equal to (x) from June 27, 2025 until June 27, 2027, 4.00%, (y) from June 28, 2026 until June 27, 2028, 2.00% and (z) thereafter, none. The Term Loan is also subject to an excess cash flow sweep and certain other customary mandatory prepayment requirements.
The Term Loan will be subject to certain financial covenants:
a consolidated total leverage ratio covenant, tested quarterly, which will be initially set at 7.25x, with step-downs to 6.50x at December 31, 2025, 6.00x at March 31, 2026, 5.25x at June 30, 2026, and additional quarterly 0.25x step-downs until a ratio of 4.00x applicable from and after September 30, 2027.
a maximum consolidated capital expenditure covenant, capped at $20 million in any fiscal year, and a sublimit of $10 million for foreign capital expenditures.
a 30-day rolling minimum average liquidity requirement of $15 million.
ABL Facility of $115 million
Obligations under the ABL Facility will mature on June 27, 2030, springing to the date that is 91 days prior to the maturity of the Term Loan.
The initial principal amount of the ABL Facility is $115 million, subject to availability under a borrowing base based on the Company’s US and UK inventory and receivables. The ABL Facility comprises of a US subfacility in an initial principal amount of $100 million (the “US Subfacility”) and a UK subfacility in an initial principal amount of $15 million (the “UK Subfacility”), in each case subject to availability under their respective borrowing bases. The US Subfacility further has a FILO tranche in a principal amount of $12.5 million, subject to availability under its borrowing base.
The ABL Facility will be available in US Dollars, Pounds Sterling and Euros, and borrowings will accrue interest at SOFR, SONIA or EURIBOR, with margins based on average daily availability ranging from 1.50% if average daily availability > $50 million to 2.00% if average daily availability < $30 million. The FILO tranche will accrue interest at a 1% higher rate. The Company is also required to pay an unused line fee of 0.25% on any unutilized commitments under the ABL Facility.
The Company will be required to comply with a maximum fixed charge coverage ratio of 1.00x, tested quarterly, during any trigger period. Such period shall be triggered upon availability dropping below the greater of 10% of the line cap and $10 million, and such period shall end upon availability exceeding this threshold for 30 consecutive days.
Warrants
In connection with the financing, TCW Group affiliates received five-year warrants for the purchase of up to 3,934,776 shares of the company’s common stock, issued in two equal tranches. The tranches have an exercise price of $1.58 and $2.07, respectively. Until the fourth anniversary after issuance, the Company has the right to repurchase up to 50% of each tranche of warrants at a price equal to $1.40 or $1.00, respectively, above the applicable exercise price. Upon a refinancing of the new credit agreement, the holders can require the Company to repurchase up to 50% of each tranche at a price equal to the stock price of the common stock at the time of repurchase less the exercise price. The warrants contain customary anti-dilution adjustments. The Company has provided the holders with certain information and registration rights, including agreeing to file a registration statement within 45 days to register the resale of the shares underlying the warrants.
The Company will file a Current Report on Form 8-K with the United States Securities Exchange Commission that will contain further details regarding the terms of the of the transactions.
Company Contact Andy Cheung Chief Financial Officer CVG IR@cvgrp.com
Investor Relations Contact Ross Collins or Stephen Poe Alpha IR Group CVGI@alpha-ir.com
About CVG
CVG is a global provider of systems, assemblies and components to the global commercial vehicle market and the electric vehicle market. We deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to risks and uncertainties. These statements often include words such as “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions. In particular, this press release may contain forward-looking statements about the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets, changes in the Class 8 and Class 5-7 North America truck build rates, performance of the global construction and agricultural equipment business, the Company’s prospects in the wire harness, and electric vehicle markets, the Company’s initiatives to address customer needs, organic growth, the Company’s strategic plans and plans to focus on certain segments, competition faced by the Company, volatility in and disruption to the global economic environment and the Company’s financial position or other financial information. These statements are based on certain assumptions that the Company has made in light of its experience as well as its perspective on historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from the anticipated results because of certain risks and uncertainties, including those included in the Company’s filings with the SEC. There can be no assurance that statements made in this press release relating to future events will be achieved. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by such cautionary statements.
In a global economy reshaped by innovation and evolving policy, European Healthcare and Life Sciences companies have a unique opportunity to accelerate growth by investing in the U.S. middle market. Our new thought leadership series—developed by leading M&A professionals from CNM LLP, Cozen O’Connor, NOBLE Capital Markets, and Pathfinder Advisors LLC—dives into the strategic, operational, and financial reasons why the time to act is now.
🔹 Compressed U.S. valuations + innovation-rich sectors 🔹 Favorable budgetary, regulatory, and M&A conditions 🔹 Cross-border synergies driving sustainable global health outcomes
This first installment lays out the business case, key advantages, and regulatory shifts creating ripe conditions for transatlantic healthcare deals. Don’t miss these insights—and get ready for the July 24 webinar that takes the conversation further.
